WebJan 9, 2024 · AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease. The acquisition will bolster AstraZeneca’s cardiorenal pipeline by adding … WebMay 20, 2024 · CinCor completed a $50 million Series A financing in 2024 and is financed by Sofinnova Investments, Sofinnova Partners, and 5AM Ventures. About CIN-107CIN-107 works through the renin-angiotensin ...
About Us CinCor Pharma Inc
WebApr 19, 2024 · WALTHAM, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) today announced its participation in the Jefferies Biotech on the Bay Summit taking place April 26-27 in Miami ... WebDec 20, 2024 · Market Update: 2024 Bond Bounce, TikTok #META #AMZN #TSLA Dec 20 binding cases letter
Valentin Svidruk’s Post - LinkedIn
WebJan 9, 2024 · 6 analysts have issued twelve-month price objectives for CinCor Pharma's stock. Their CINC share price forecasts range from $30.00 to $67.00. On average, they expect the company's stock price to reach $46.67 in the next year. This suggests a possible upside of 60.6% from the stock's current price. View analysts price targets for CINC or … WebFeb 24, 2024 · finance.yahoo.com - March 13 at 7:59 AM: CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat finance.yahoo.com - February 21 at 10:08 AM: As demand for Covid vaccines falls, AstraZeneca lines up 'blockbuster' … WebJan 9, 2024 · (Reuters) -AstraZeneca said on Monday it had struck a deal to buy U.S.-based drug developer CinCor Pharma Inc for up to $1.8 billion to increase its stock of heart and kidney drugs. Core to the deal is CinCor's experimental therapy baxdrostat, which is in development to treat conditions including high blood pressure and chronic kidney … binding case